arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.
You may also be interested in...
RuiYi Signs On New Partners To Develop Anti-IL6 mAb In China
The China-U.S. hybrid signs on Shanghai-based Genor Biopharma in a co-development deal and contract manufacturer CMC Biologics to develop a cell line for RYI-008 for global manufacturing.
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.